Comparison 15. Mogamulizumab vs. Vorinostat.
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 15.1 Objective response rate | 1 | Risk Ratio (M‐H, Fixed, 95% CI) | Subtotals only |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.